Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook 2024

Annual Industry Ranking And Forecast

VIEW NOW

Featured Stories


A Sneak Peak At Pfizer’s Next-Generation ADC Pipeline

Antibody-drug conjugates remain a hot area of cancer drug development and Pfizer showed investors some of the novel targets and improved payloads it is advancing.

Cancer Clinical Trials Innovation

In Investing, Oncology Is Still King, But Other Indications Joining The Royal Court

Investing in oncology has diminished as more focus goes to clinical-stage firms, while investment in preclinical companies in areas like neurology has been heating up.

Deals Financing Neurology

Abingworth Adds Stakes To Gilead’s Trodelvy Gamble

The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.

Commercial Clinical Trials Companies

Asia Spotlight

China HPV Demand Shaping Merck But Competitors Catching Up

Multiple factors were behind Merck & Co’s rise to ace AstraZeneca and others to become the leading pharma multinational in the world’s second-largest pharma market in 2023, including partnerships and competition and a strong position in the growing HPV vaccine sector.

China Commercial

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Finance Watch: FogPharma’s Platform Against Unreachable Targets Attracts $145m Series E

Private Company Edition: FogPharma raised $145m for its clinical-stage drug and earlier programs after bringing on former Johnson & Johnson R&D head Mathai Mammen as CEO last year. Also, BlossomHill closed a $100m series B round and Kenai emerged with $82m in series A cash.

Financing Innovation

Pipeline Watch: Four Approvals And 21 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Finance Watch: Denali, Avidity And Others Chase Big Money Via Private Placements

Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.

Financing Business Strategies

Executives On The Move: Joseph Papa Joins Emergent BioSolutions As CEO Among Other Industry Moves

Recent moves within the industry include changes at the top for Ocular Therapeutix and Rayzebio, plus a new CEO for Bellicum Pharmaceuticals.

Executive Changes Leadership
Interviews

Kymera Puts Emphasis On Immunology In New Growth Phase

CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.

Immune Disorders Business Strategies

Incyte Enters A Data-Rich Year On Path To Portfolio Diversification

Incyte’s Jakafi-dominated portfolio gained Opzelura as a second source of significant revenue in 2021. While further diversification has been limited, new and existing R&D assets may deliver upside in 2024.

Strategy Cancer

Toward The Global Big Pharma League: Yuhan’s Ambitions After Leclaza

With Leclaza as a foothold, the next couple of years will be crucial for Yuhan’s ambition to become a top 50 global pharma firm. R&D president Yeul Hong Kim shares how he intends to shape the leading Korean company's efforts to compete with its global rivals.

South Korea Business Strategies

Ambitious AAX Wants To Be Key Player In Next-Generation Antibodies

Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma. 

Sweden Emerging Company Profile
See All
Graphics

Weighty Matters: The Obesity Market Now… And In Years To Come

INFOGRAPHIC: This overview of the obesity market shows the biggest money-spinners in terms of products and mechanisms, the biggest investors and dealmakers – and looks at how some of the notable current and potential future therapies stack up in the clinic.

Clinical Trials Commercial

Downturn Hit UK Biotech In 2023 But New Pension Funds Could Fuel Growth

Funding for UK biotechs shrank again last year but sector leaders see hope of green shoots in 2024.

Companies Deals

Biopharma’s Winners And Losers Of 2023: Obesity Drugs Reshape Big Pharma

Novo Nordisk and Eli Lilly kickstarted an obesity drug revolution in 2023, just as investors cooled on biopharma’s vaccine saviors as the world looked to move on from COVID-19.

Commercial Companies

Top 10 Best-Selling Drugs Of Q3 2023: Ozempic Challenges Humira As Keytruda Extends Leadership

As Merck & Co’s checkpoint inhibitor Keytruda further cemented its position at the top of the best-selling drugs list, biosimilar-challenged Humira sales fell once again. Meanwhile, Novo Nordisk’s diabetes injection Ozempic continued its ascent.

Market Intelligence Sales & Earnings
See All
Recent Stories

Finance Watch: FogPharma’s Platform Against Unreachable Targets Attracts $145m Series E

Private Company Edition: FogPharma raised $145m for its clinical-stage drug and earlier programs after bringing on former Johnson & Johnson R&D head Mathai Mammen as CEO last year. Also, BlossomHill closed a $100m series B round and Kenai emerged with $82m in series A cash.

Financing Innovation

Akero’s 96-Week Fibrosis Data Sparkle In MASH

Akero’s Phase IIb study of FGF21 analog efruxifermin demonstrates long-term reduction or resolution of fibrosis, but concerns about bone mineral density declines may confound the data.

Clinical Trials Drug Approval Standards

Bayer Bets Big On External Innovation With BridgeBio Acoramidis Pact

The German major's internal R&D fortunes in the cardiovascular space have been mixed, with asundexian faltering in a recent atrial fibrillation trial, so getting hold of the European rights to BridgeBio's recently-filed ATTR-CM therapy is a timely boost.

Cardiovascular Deals

Vivoryon Gazes Into The Abyss

A comprehensive mid-stage failure in Alzheimer’s leaves the company with very faint hopes.

Clinical Trials Neurology

Publisher’s Spotlight: Citeline News And Insights App

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

BioPharmaceutical

Pipeline Watch: Four Approvals And 21 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

BMS’ Boerner Bets On AI-Driven R&D In India, Points To Potential For MS, Lupus Drugs

BMS CEO Boerner made predictions of AI being a game changer for R&D in India come true with plans to conduct AI-driven small molecule drug research in India, set to house the company’s largest R&D site outside of the US by next year. He also spoke of bringing its drugs to treat multiple sclerosis and Lupus to the country

Business Strategies Research & Development

First Digital Therapeutic App Filed For Approval In Expanding Japan ADHD Market

A pioneering approval filing for a therapeutic app by Shionogi is set to herald expansion of ADHD therapies beyond the pill in Japan, along with growth in the pediatric segment for the disorder.

Japan Digital Health

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: optimistic outlook for biopharma IPOs; Boehringer’s promising MASH results; Viking emerges as obesity contender; Incyte looks to portfolio diversification; and a look at China’s HPV vaccine market.

Commercial Clinical Trials

Cardiff’s Move Into First-Line mCRC Backed By Data From Discontinued Study

Based on advice from the FDA, Cardiff is testing its PLK1 inhibitor onvansertib in first-line metastatic colorectal cancer; data from a discontinued second-line trial may support the hypothesis.

Clinical Trials Drug Approval Standards

Finance Watch: Denali, Avidity And Others Chase Big Money Via Private Placements

Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.

Financing Business Strategies

Taking On Vyvgart In Myasthenia Gravis

Argenx has aggressive market expansion plans for Vyvgart. It also has several late-stage challengers in what is becoming a dynamic market.

Inflammation Clinical Trials
UsernamePublicRestriction

Register